Stacy Emerson
Psychiatric/Mental Health · Kennett, MONPI 1942508999
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,700 of the $25,366 with a category attached, or 73.7%. AbbVie accounts for 89.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $13,727 and has fallen 57.7% since, to $5,813 in 2025. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $124.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Alkermes, Inc.$957
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$387
- Teva Pharmaceuticals USA, Inc.$335
- Johnson & Johnson$286
- Otsuka America Pharmaceutical, Inc.$183
- plus $546 from 9 others
What the payments were for
- Speaking & faculty fees$18,70074%
- Travel & lodging$2,50810%
- Food & beverage$4,06216%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $22,672 |
| Alkermes, Inc. | 34 | $957 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $387 |
| Teva Pharmaceuticals USA, Inc. | 7 | $335 |
| Johnson & Johnson | 18 | $286 |
| Otsuka America Pharmaceutical, Inc. | 11 | $183 |
| Neurocrine Biosciences, Inc. | 7 | $138 |
| Merck | 6 | $106 |
| Indivior Inc. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| Lundbeck LLC | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$21,224
- LYBALVI$460
- ARISTADA$420
- UZEDY$238
- ARISTADA INITIO$105
How this compares
$25,366 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 78 | $276,259 |
| Invega TrinzaPaliperidone Palmitate | 14 | $151,204 |
| VraylarCariprazine Hcl | 95 | $136,817 |
| IngrezzaValbenazine Tosylate | 11 | $91,549 |
| Abilify MaintenaAripiprazole | 17 | $49,022 |
| RexultiBrexpiprazole | 19 | $28,883 |
| TrintellixVortioxetine Hydrobromide | 55 | $26,386 |
| SpravatoEsketamine Hcl | 14 | $25,207 |
| BelsomraSuvorexant | 44 | $19,230 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $8,458 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $6,513 |
| FetzimaLevomilnacipran Hcl | 13 | $6,476 |
| Varenicline Tartrate | 34 | $6,280 |
| Duloxetine Hcl | 309 | $6,120 |
| Doxepin Hcl | 187 | $5,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato | $286 | $452,671106 claims |
| AbbVieVraylar, Fetzima | $22,672 | $143,293108 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $138 | $91,54911 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $183 | $77,90536 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $66 | $26,38655 claims |
| MerckBelsomra | $106 | $19,23044 claims |
| Axsome Therapeutics, Inc.Auvelity | $23 | $8,45816 claims |
| Indivior Inc.Suboxone | $71 | $6,51317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Kennett
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
- Karin BaughmanSpringfield$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.